CD8A and non-small cell lung carcinoma: Hurkmans et al. suggested that the combination of PD-L1 expression, TML, CD8+ T-cell infiltration, and HLA class-I functions could be used to predict the efficiency of immunotherapy in NSCLC patients (Hurkmans et al., 2020).